| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director | EVP, Strategy And Bus. Dev. +1 more
3 companies
Koppel Adam serves as a Director, 10% Owner at KLRA and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 2 buys and 2 sells. Those positions are worth an estimated $23.0M at current prices.
The biggest single holding is SLDB (~$22.3M) as Director, 10% Owner. Net of sales, the recent Form 4 record there shows accumulation of 300,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. Common Stock | Director, 10% Owner | Buy | 1,562,500 | $16.00 | $25,000,000.00 | +7.4% | |
| Jan 30, 2018 | SLDB Solid Biosciences Inc. | Director | Buy | 300,000 | $16.00 | $4,800,000.00 | +17.8% | |
| Jun 6, 2016 | BIIB Biogen Inc. | EVP, Strategy And Bus. Dev. | Sell | 555 | $290.00 | $160,950.00 | -18.8% | |
| Apr 6, 2016 | BIIB Biogen Inc. | EVP, Strategy And Bus. Dev. | Sell | 102 | $275.00 | $28,050.00 | -5.2% |